Ventracor chalks up first revenues

By Ruth Beran
Tuesday, 20 September, 2005

Ventracor (ASX:VCR) has received its first revenues, in the form of a cheque from the University of Maryland Medical Centre as payment for a VentrAssist left ventricular assist device (LVAD) recently implanted in a patient as part of its US clinical trial.

The company previously indicated it would reach the milestone before the end of 2005.

Related News

Novel antibiotic activates 'suicide' mechanism in superbug

Researchers have discovered a new class of antibiotic that selectively targets Neisseria...

Modifications in the placenta linked to psychiatric disorders

Schizophrenia, bipolar disorder and major depression disorder are the neuropsychiatric disorders...

ADHD may be linked with an increased risk of dementia

An adult brain affected by attention deficit hyperactivity disorder (ADHD) presents modifications...

Content from other channels on our network

JCU develops 'world first' bendable ceramic

Bayan licenses Australian solar cell recycling technology

Visy smashes recycled glass content target in New Zealand

Nuclear places Australia's aluminium smelters at risk: analysis

Construction begins on Central Coast Food Manufacturing Innovation Hub

Safeguarding food and beverage production processes

Australia's Industrial Future Takes Centre Stage in Sydney This July

Premium snack maker meets growing demand

Sauerkraut better than raw cabbage for gut health

Heat exchangers expand ginger beer production

Stigma around lung disease and cancer must go

Queensland announces its Hospital Rescue Plan

Report card shows "alarming" levels of ramping

NSW commits additional $2.8m for paediatric palliative care

High-five for a sustainable path to better hand hygiene

  • All content Copyright © 2025 Westwick-Farrow Pty Ltd